



## Supplementary Materials


### Supplementary Figures




**Fig. S1.** Cyotoxicity test of Oxo-M and/or 4-PPBP with rat TSCs: Live/dead assay (**A**) and quantification of live cell numbers (**B**) (n = 5 per group).



**Fig. S2.** Expressions of tenogenic markers in CD146<sup>-</sup> tendon cells with Oxo-M and 4-PPBP by 1 wk (n = 5 per group; \*:p<0.05 compared to control).



**Fig. S3.** Verification of transfection efficiency of siRNA with RFP (A) and GAPDH (B) (n = 5 per group: \*:p<0.00001 compared to the controls).



**Figure S4.** Translational pathway for development of a regenerative injection therapy for tendon injuries. Our findings support the high efficiency of Oxo-M and 4-PPBP to improve tendon healing with minimal cytotoxicity and their specificity via endogenous tendon stem/progenitor cells. We have also suggested a potential controlled delivery vehicle for Oxo-M and 4-PPBP that can be simply injected into tendon leading to endogenous regeneration.